Daniel Von Hoff, MD, FACP


Daniel D. Von Hoff, M.D., F.A.C.P., is currently Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute. He is also a Clinical Professor of Medicine, University of Arizona. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California San Francisco. Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely: fludarabine, docetaxel, gemcitabine, nelarabine, and capecitabine. He and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers. He is currently serving a six-year term on the National Cancer Advisory Board and has served on the FDA's Oncology Advisory Committee. Von Hoff is a past president of the American Association for Cancer Research, was on the AACR and the American Society of Clinical Oncology's Board of Directors, Clinical Cancer Research and Cancer Research.